Menu Search
Equities

Genincode PLC

9PL:FRA

Genincode PLC

Actions
  • Price (EUR)0.0865
  • Today's Change-0.001 / -0.57%
  • Shares traded-1.00
  • 1 Year change-41.55%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 14:29 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

  • Revenue in GBP (TTM)1.72m
  • Net income in GBP-6.73m
  • Incorporated2018
  • Employees28.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.